Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013 –2015) as part of the program to assess Ceftolozane-Tazobactam susceptibility (PACTS) surveillance program

This study evaluated the in vitro activity of ceftolozane-tazobactam and comparators against 2647 Enterobacteriaceae and 355 Pseudomonas aeruginosa non-duplicate isolates collected from hospitalized patients with bloodstream infections in US hospitals from 2013 to 2015.Ceftolozane-tazobactam (95.5% susceptible), amikacin (99.2% susceptible), and meropenem (98.4% susceptible) were the most active against Enterobacteriaceae. For Enterobacteriaceae, 1.4% (n=37) were carbapenem-resistant (CRE) and 10.2% (n=271) exhibited an ESBL non-CRE phenotype.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Source Type: research